Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS – News-Medical.net
News-Medical.net |
Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS
News-Medical.net Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar … |
